Company profile
Regen BioPharma, Inc.
OTC: RGBP · Healthcare · Biotechnology
#998 of 1,422 Healthcare companies by revenue42nd-percentile growth
EA Score
35DFH 20DQ 50GM 54SS 22
v0.1 · 65/100 weight · provisional
↑ disclosure history, 3-yr revenue growth · ↓ workforce scale, balance-sheet leverage
Methodology →Revenue TTM
$209.1k
Rev growth YoY (TTM)
-11.6%
Net income (FY)
-$1.3M
Employees
1
as of 2026-08-30
Market cap
$6.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$236.6k$236.6k2025
Net income-$1.3M-$1.3M2025
Operating income-$338.5k-$338.5k2025
Total assets$274.6k$274.6k2025
Liabilities$6.6M$6.6M2025
Equity-$6.3M-$6.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Regen BioPharma, Inc.’s revenue?
Regen BioPharma, Inc. booked $236.6k in FY2025 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -538.8% net margin.
Peers · Healthcare
LiveWire Ergogenics, Inc.——Sproutly Canada Inc.——Geron Corporation51DBlueberries Medical Corp.32DFamily Office of America Inc.37DHAVN Life Sciences Inc.——Neighbors
San Diego →Key facts
CEODavid Raymond Koos
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Mesa, CA
ExchangeOTC: RGBP
Employees1
IPO date2014-10-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.